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Abstract
Background: Calcitonin gene-related peptide (CGRP) is a 37-amino-acid vasodilatory neuropeptide that binds to
receptor activity-modifying protein 1 (RAMP1) and the calcitonin receptor-like receptor (CLR). Clinical and preclinical
evidence suggests that CGRP is associated with hip and knee joint pain; however, the regulation mechanisms of
CGRP/CGRP receptor signaling in synovial tissue are not fully understood.
Methods: Synovial tissues were harvested from 43 participants with radiographic knee osteoarthritis (OA; unilateral
Kellgren/Lawrence (K/L) grades 3–4) during total knee arthroplasty. Correlationships between the mRNA expression
levels of CGRP and those of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and cycloxygenase-2 (COX-2)
were evaluated using real-time PCR analysis of total RNA extracted from the collected synovial tissues. To
investigate the factors controlling the regulation of CGRP and CGRP receptor expression, cultured synovial cells
were stimulated with TNF-α, IL-1β, IL-6, and prostaglandin E2 (PGE2) and were also treated with PGE2 receptor
(EP) agonist.
Results: CGRP and COX-2 localized in the synovial lining layer. Expression of COX-2 positively correlated with
CGRP mRNA expression in the synovial tissue of OA patients. The gene expression of CGRP and RAMP1 increased
significantly in synovial cells exogenously treated with PGE2 compared to untreated control cells. In cultured
synovial cells, CGRP gene expression increased significantly following EP4 agonist treatment, whereas RAMP1
gene expression increased significantly in the presence of exogenously added EP1 and EP2 agonists.
Conclusions: PGE2 appears to regulate CGRP/CGRP receptor signaling through the EP receptor in the synovium
of knee OA patients.
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Background
The main symptom of knee osteoarthritis (OA) is joint
pain. Nonsteroidal anti-inflammatory drugs (NSAIDs)
are the most widely used pharmaceuticals for treating
OA [1]. Although NSAIDs are effective for reducing
pain [2], drugs in this class are nephrotoxic and signifi-
cantly increase the risk of gastrointestinal ulceration and
bleeding and cardiovascular events [3]. For these rea-
sons, the long-term use of NSAIDs is contraindicated in
many OA patients, and a need therefore exists for the
development of more effective and specific drugs for OA
pain management.
Calcitonin gene-related peptide (CGRP) is a 37-amino-
acid vasodilatory neuropeptide that binds to receptor
activity-modifying protein 1 (RAMP1) and the calcitonin
receptor-like receptor (CLR) [4]. Clinical and preclinical
evidence suggests that CGRP is associated with hip and
knee joint pain [5–14]. For example, CGRP-positive cells
were immunohistochemically detected in the synovial
tissue of OA patients [8, 11]. CGRP mRNA was also ob-
served in the synovial tissue of developmental dysplasia
of the hip patients [10], and the mRNA and protein
expression of CLR and RAMP1 were detected in cul-
tured synovial cells harvested from OA patients [5]. In
addition, CGRP antagonist administration to rat OA
models led to the relief of pain [6, 7]. Taken together,
these observations suggest that CGRP/CGRP receptor
signaling in synovial tissue plays an important role in
OA pathology. However, the regulatory mechanisms of
CGRP and its receptor in synovial tissue are not fully
understood.
Here, we investigated the regulation of CGRP and the
CGRP receptor in the synovium of 43 knee OA patients.
Methods
Reagents
Human recombinant interleukin-6 (IL-6), interleukin-1β
(IL-1β), and tumor necrosis factor-α (TNFα) were pur-
chased from Biolegend (San Diego, CA, USA). Prostaglan-
din E2 (PGE2) and butaprost (EP2 agonist) were
purchased from Sigma (St. Louis, MO, USA). Iloprost
(EP1 agonist), sulprostone (EP3 agonist), and CAY10598
(EP4 agonist) were purchased from Caymann (Ann Arbor,
MI, USA).
Patients
A total of 43 participants with radiographic knee OA
(unilateral Kellgren/Lawrence (K/L) grades 3–4) under-
went total knee arthroplasty at our institution. The study
included 9 men and 34 women aged 50–87 years (mean ±
SD, 73.6 ± 8.7 years) with a mean ± SD body mass index
(BMI) of 26.1 ± 3.9 kg/m2 (range 20.3–36.7). The K/L
grades of the 43 operated knees were comprised of 42 %
grade 3 and 58 % grade 4. A sample of synovial tissue was
harvested from each operated knee during the total knee
arthroplasty surgery. A portion of each synovial tissue
sample was fixed with 4 % paraformaldehyde formalin for
48 h for histological analysis, and the remaining sample
was stored at −80 °C until used for RNA extraction for
real-time PCR analysis. Synovial tissues from 12 patients
were also used for cell culture. Informed consent for par-
ticipation in this study was obtained from each patient on
the day before surgery.
Immunohistochemistry
To determine the localization of CGRP and cyclooxgenase
2 (COX-2), the paraformaldehyde-fixed synovial tissues
samples were embedded in paraffin and sliced into 3-μm-
thick sections. Sections were immunohistochemically
stained with rabbit polyclonal primary antibody against
COX-2 (Abcam, Cambridge, MA) or mouse monoclonal
primary antibody against CGRP (Abcam) using the
streptavidin-biotin-peroxidase method (Histofine SAB-PO
Kit; Nichirei, Tokyo, Japan).
Real-time PCR analysis
Total RNA was isolated from the harvested synovial
tissue using TRIzol reagent (Invitrogen, Carlsbad, CA)
following the manufacturer’s protocol. The extracted
RNA was used as template for first-strand cDNA synthe-
sis of CGRP, RAMP1, CLR, COX-2, TNF-α, IL-1β, and
IL-6 using SuperScript III RT (Invitrogen) in reaction
mixtures composed of 2 μL cDNA, 0.2 μM specific pri-
mer pair, 12.5 μL SYBR Premix Ex Taq (Takara, Kyoto,
Japan), and nuclease-free water in a final volume of
25 μL. The primers were designed using Primer Blast
software and were synthesized by Hokkaido System
Science Co., Ltd. (Sapporo, Japan). The sequences of the
PCR primer pairs are listed in Table 1. The specificity of
the amplified products was examined by melt curve
analysis. Quantitative PCR was performed using a Real-
Time PCR Detection System (CFX-96; Bio-Rad, CA,
USA) to determine relative mRNA expression levels.
The PCR cycle parameters were as follows: 95 °C for
1 min, followed by 40 cycles of 95 °C for 5 s and 60 °C
for 30 s. mRNA expression was normalized to the levels
of GAPDH mRNA.
Synovial cell culture
To investigate the factors regulating CGRP and CGRP
receptor expression, synovial cells were harvested from
synovium collected from the knees of 12 OA patients.
Mononuclear cells were isolated from synovium by
digestion of the tissue with 40 ml of 0.1 % type I col-
lagenase. The obtained cells were cultured in α-MEM
in 6-well plates. After 7 days, the cells harvested from
six patients were stimulated with human recombinant
IL-6 (100 ng/ml), IL-1β (50 ng/ml), TNF-α (10 ng/ml), or
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PGE2 (10 μM) for 24 h. The cells harvested from another
six patients were stimulated with 10 μM iloprost,
butaprost, sulprostone, or CAY10598 for 24 h. After the
treatments, cells were harvested for RNA isolation, as
described above, and CGRP, RAMP1, and CLR expression
was analyzed by RT-PCR. Cells were also harvested for
protein extraction, as described below, and RAMP1 pro-
tein expression was analyzed by Western blotting.
Western blotting
To investigate RAMP1 protein expression, cells har-
vested from five patients were stimulated with 10 μM
PGE2, iloprost, butaprost, sulprostone, or CAY10598 for
24 h. Synovial cells were then lysed in RIPA buffer
(Wako) supplemented with a protease inhibitor cocktail
(Roche), and the protein concentration for each tissue
extract was determined using the bicinchoninic acid
(BCA) assay (Pierce, Rockford, IL, USA). Protein ex-
tracts (10 μg/lane) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and were elec-
trophoretically transferred onto polyvinyl difluoride
membranes, which were then blocked with PVDF block-
ing reagent (Toyobo, Osaka, Japan) for 1 h. The blocked
membranes were incubated overnight at 4 °C with rabbit
monoclonal primary antibodies against RAMP1
(Abcam). The primary antibodies were diluted 1:1000
with Can Get Signal Solution 1 (Toyobo). The mem-
branes were washed with PBS-T and incubated with the
secondary antibodies (GE Healthcare, NJ, USA), which
were diluted 1:1000 with Can Get Signal Solution 2
(Toyobo). Immunoreactive proteins were visualized by
chemiluminescence using ImmunoStar LD reagent (Wako,
Tokyo, Japan), and images were captured using a LAS-
5000 system (Fuji Film, Tokyo, Japan).
Statistical analysis
Pearson’s correlation coefficient was used to evaluate the
relationship between CGRP and the examined stimula-
tory factors. A p value of <0.01 was considered statisti-
cally significant for the correlation coefficient analysis.
Differences between the untreated and treated synovial
cells were compared using one-way ANOVA with Fisher’s
least significant difference test. A p value of <0.05 was
considered statistically significant. Cook’s distance statis-
tical test was used to identify potential statistical outliers
that influence the linear regression coefficient analysis. All
statistical analyses were performed using SPSS software
(v. 19.0; SPSS, Chicago, IL, USA).
Results
Relationship between CGRP, inflammatory cytokines, and
COX-2 expression levels in synovial tissue of OA patients
Seven synovial tissue samples had seven outliers (two for
IL-6 and five for IL-1B), which were excluded from the
analysis. The relationship between CGRP mRNA expres-
sion and the mRNA expression levels of several inflam-
matory factors in synovial tissue of OA patients was first
examined. The expression levels of cyclooxgenase 2
(COX-2) were positively correlated with those CGRP,
whereas no correlation between the mRNA expression
levels of IL-6, IL-1β, or TNF-α and those of CGRP were
detected in the synovial tissue (Fig. 1).
Localization of COX-2 and CGRP in synovial tissue of OA
patients
As real-time PCR analysis detected a correlation between
CGRP and COX-2 mRNA expression, immunohistochem-
ical analysis was performed to investigate the localization
of CGRP and COX-2. The analysis revealed that both
COX-2 and CGRP protein localized in the synovial lining
layer (Fig. 2).
Effect of inflammatory cytokines and PGE2 on CGRP
expression in cultured synovial cells
The effects of inflammatory cytokines and PGE2 on the
mRNA expression of CGRP and its associated receptors
in synovial tissue of the knee OA patients were next
examined. As TNF-α and IL-1β stimulate CGRP ex-
pression in several cell lines in vitro [15, 16], these
inflammatory cytokines were used as positive controls.
Real-time PCR analysis revealed that the gene expression
of CGRP increased significantly in synovial cells in the
presence of exogenously added TNF-α, IL-1β, and PGE2
compared to untreated control cells, but was not
affected in IL-6-treated synovial cells (Fig. 3a). RAMP1 ex-
pression increased upon PGE2 stimulation, but remained
Table 1 Sequences of the primers used in this study
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relatively unchanged in cells treated with TNF-α, IL-1B,
and IL-6 (Fig. 3b). No marked differences in CLR expres-
sion were detected among the stimulated and untreated
synovial cells for any of the examined factors (Fig. 3c).
Effect of EP1-4 agonists on CGRP and CGRP receptor
expression in cultured synovial cells
PGE2 acts via four different receptor subtypes: EP1, EP2,
EP3, and EP4. Next, the regulation of CGRP and
RAMP1 by EPs was investigated using EP1-4 agonists.
Real-time PCR analysis revealed that the gene expression
of CGRP increased significantly in synovial cells in the
presence of exogenously added EP4 agonist compared to
untreated control cells (Fig. 4a). The expression of CGRP
was not affected in EP1, EP2, and EP3 agonist-treated
synovial cells (Fig. 4a). In addition, RAMP1 mRNA
expression and protein levels increased significantly in
synovial cells treated with exogenously added EP1 and
EP2 agonists compared to untreated control cells, but was
not affected in EP3 or EP4 agonist-treated synovial cells
(Figs. 4b and 5). No differences in CLR expression were
detected between the untreated and agonist-treated cells
(Fig. 4c).
Discussion
In the present study investigating the mechanisms
underlying the regulation of CGRP in the synovial tissue
of knee OA patients, a correlation between CGRP and
COX-2 expression was detected, and both CGRP and
COX-2 localized in the synovial lining layer. In addition,
the treatment of synovial fibroblast cultures with PGE2
and EP4 agonist also stimulated CGRP expression, and
Fig. 1 Correlation between mRNA expression levels of CGRP and those of inflammatory cytokines and COX-2 in synovial tissue. The correlation
between CGRP and Cox-2 (a), IL-6 (b), IL-1β (c), and TNF-α (d) mRNA expression levels in synovial tissue harvested from 43 knee OA patients.
*Pearson’s coefficient p < 0.001
Fig. 2 Immunolocalization of CGRP and COX-2 in synovial tissue. Immunolocalization of CGRP (a) and Cox-2 (b). Scale bar = 100 μm
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PGE2, EP1, and EP2 agonist stimulated RAMP1 expres-
sion. Taken together, these findings suggest that the
PGE2/EP signaling pathway regulates CGRP/CGRP re-
ceptor signaling in synovial fibroblasts.
Recent behavioral studies have reported that CGRP/
CGRP receptor signaling is regulated by inflammatory
cytokines, growth factors, and PGE2 in neural cells
[15, 17], epithelial cells [16], and immune cells [18–20].
In trigeminal ganglion neurons, IL-1β and TNF-α induced
CGRP release in [15, 16], and IL-1β additionally promoted
COX-2 and PGE2 synthesis, resulting in elevated CGRP
release [17]. Liu et al. [16] reported that IL-1β also stimu-
lates CGRP release from human type II alveolar epithelial
cells [16]. In the present study, COX-2 expression posi-
tively correlated with that of CGRP in synovial tissue, and
PGE2, which is the enzymatic product of COX-2, also
stimulated CGRP gene expression. In contrast, exogen-
ously added TNF-α and IL-1β stimulated CGRP expres-
sion in vitro, but no significant correlation was detected
between TNF-α- or IL-1β-induced CGRP mRNA expres-
sion levels in the synovial tissue from knee joints of OA
patients. In a recent study, Nakata et al. [21] demonstrated
that cyclic compressive loading on a 3D-cultured con-
struct of human synovial fibroblasts upregulates PGE2
and COX-2 in the absence of IL-1β or TNF-α stimulation.
These results suggest that CGRP may be regulated by
PGE2 in an IL-1β- and TNF-α-independent manner in
the synovium of OA patients.
RAMP1 is required for the translocation of CLR to the
cell surface and also participates in ligand binding and is
therefore essential for CGRP receptor signaling [22, 23].
Consistent with these properties, the overexpression of
RAMP1 sensitizes vascular smooth muscle cells and tri-
geminal ganglia neurons to CGRP. A recent study re-
ported that RAMP1 mRNA expression was detected in
synovial cell culture isolated from OA patients [5]; how-
ever, the underlying regulatory mechanisms controlling
this expression were not elucidated. Here, we also de-
tected RAMP1 expression in cultured synovial cells and
found that PGE2 regulated not only CGRP expression
but also that of the RAMP1 in synovial cells.
PGE2, which is a major pro-inflammatory prostanoid
and plays a role in nociceptive processing, acts via four
different G-protein-coupled receptor subtypes: EP1, EP2,
EP3, and EP4 [24, 25]. EP1 receptors are involved in
mechanical sensitization at the spinal cord level. Intra-
thecal injection of the EP1-selective antagonist ONO-
8711 in the carrageenan model of inflammatory pain
and oral administration of ONO-8711 in a model of
postoperative pain improved mechanical hyperalgesia
Fig. 3 Effects of cytokines and PGE2 on CGRP and CGRP receptor expression in synovial cell culture. Real-time polymerase chain reaction analysis
for a calcitonin gene-related peptide (CGRP), b receptor activity-modifying protein 1 (RAMP1), and c calcitonin receptor-like receptor (CLR) gene
expression in synovial cell culture. Synovial cells were stimulated with human recombinant IL-6 (100 ng/ml), IL-1β (50 ng/ml), TNF-α (10 ng/ml), or
PGE2 (10 μM) for 24 h prior to the extraction and analysis of total RNA. All data are presented as the mean ± standard error (n = 6). *p < 0.05
compared with the untreated control
Fig. 4 Effects of EP agonists on CGRP and CGRP receptors in synovial cell culture. Real-time polymerase chain reaction analysis for a calcitonin
gene-related peptide (CGRP), b receptor activity-modifying protein 1 (RAMP1), and c calcitonin receptor-like receptor (CLR) gene expression in
synovial cell culture. Synovial cells were stimulated with 10 μM iloprost (EP1), butaprost (EP2), sulprostone (EP3), or CAY10598 (EP4) for 24 h prior to the
extraction and analysis of total RNA. All data are presented as the mean ± standard error (n = 6). *p < 0.05 compared with the untreated control
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[26, 27]. The EP2 receptor also contributes to spinal
pain sensitization during inflammatory pain states [28,
29]. Furthermore, increased levels of PGE2 upregulates
expression of the EP4 receptor subtype in rat sensory
dorsal root ganglion (DRG) neurons [30]. Southall et al.
[31] reported that the sensitization of sensory neurons is
mediated mainly through EP4 receptors and does not
proceed via EP3 receptors. Here, we found that the
treatment of synovial cell cultures with EP4 agonist led
to increased CGRP expression and that the exogenous
addition of EP1 and EP2 agonists increased RAMP1 ex-
pression. Based on the findings of these previous and
present studies, PGE2 appears to regulate CGRP/CGRP
receptor signaling through differential EP receptors in
the synovium of knee OA patients.
A number of clinical trials have demonstrated that
CGRP and CGRP receptor antagonists are efficacious for
migraine treatment [32–35]. In addition, humanized
antibody against CGRP (LY295174) relieved pain in a rat
OA model [6, 7], and clinical trials of anti-CGRP anti-
body in human OA patients are underway [36]. In the
present study, although the relationship between CGRP
expression levels and pain in OA patients was not deter-
mined, our findings related to CGRP and CGRP receptor
regulation in synovial tissue may provide valuable infor-
mation for developing future pain treatments for OA.
Several limitations of the present study warrant
mention. First, the lack of inclusion of a control, non-
osteoarthritic patient population is needed to confirm
whether CGRP levels are elevated in the synovial tissues
of OA patients as compared to non-OA patients. Second,
it remains to be determined if the elevation of CGRP
levels contributes to OA pain. Third, CGRP mRNA ex-
pression and localization of CGRP was examined using
real-time PCR and immunohistochemistry, respectively;
however CGRP protein concentration was not determined
in the synovial tissue or cell culture supernatant. Finally,
the effects of CGRP on synovial cells were not evaluated.
Conclusions
In conclusion, CGRP/CGRP receptor signaling in syn-
ovial tissue of OA patients is regulated by PGE2 and
PGE2 receptor signaling. The findings presented here may
provide useful information for developing therapeutic
strategies for managing OA pain.
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